{"id":"NCT03440385","sponsor":"Celgene","briefTitle":"Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease","officialTitle":"Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-07","primaryCompletion":"2023-11-21","completion":"2023-11-21","firstPosted":"2018-02-22","resultsPosted":"2024-12-05","lastUpdate":"2024-12-05"},"enrollment":606,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn Disease"],"interventions":[{"type":"DRUG","name":"Ozanimod","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Administration of oral Ozanimod","type":"EXPERIMENTAL"},{"label":"Administration of Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.","primaryOutcome":{"measure":"Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150","timeFrame":"Week 12","effectByArm":[{"arm":"Ozanimod","deltaMin":29.8,"sd":null},{"arm":"Placebo","deltaMin":30.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8125"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":368,"countries":["United States","Australia","Austria","Bulgaria","Canada","China","Colombia","Finland","France","Georgia","Germany","Greece","Hong Kong","Hungary","Israel","Lithuania","Netherlands","Poland","Portugal","Russia","Senegal","Serbia","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["36208720"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":404},"commonTop":["Crohn's disease"]}}